At the annual meeting of stockholders of Vapotherm, Inc. held on June 22, 2021, the company’s stockholders elected each of Lori Knowles and Mary Beth Moynihan as a new Class III director of the company effective immediately. Marina Hahn did not stand for re-election as a Class III director of the Company at the 2021 Annual Meeting and therefore concluded her term as a Class III director. Lori Knowles will serve as a member of the Compensation Committee, replacing Marina Hahn, and Mary Beth Moynihan will serve as a member of the Audit Committee of the Board of Directors, in each case effective immediately.
Vapotherm, Inc. is a developer and manufacturer of advanced respiratory technology. It develops non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. It is focused on the care of patients suffering from respiratory distress, whether associated with lung diseases, such as chronic obstructive pulmonary disease, congestive heart failure, pneumonia, asthma, and COVID-19 or other systemic conditions. Its device solutions are focused on High Velocity Nasal Insufflation, which delivers non-invasive ventilatory support to patients by providing heated, humidified, oxygenated air at high velocities through a small-bore nasal interface, and on closed loop control systems, such as its Oxygen Assist Module, designed to automatically maintain a patients pulse oxygen saturation levels within a specified range for a defined period of time. Its digital solutions are focused on remote patient monitoring, using algorithms to predict respiratory episodes.
VAPOTHERM, INC. 
